How to Buy Oculis Holding Ag Stock
Oculis Holding Ag
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.
Oculis Holding Ag stock last closed at $24.99, down 0.04% from the previous day, and has increased 27.11% in one year. It has overperformed other stocks in the Biotechnology industry by 0.6 percentage points. Oculis Holding Ag stock is currently +78.5% from its 52-week low of $14.00, and -18.55% from its 52-week high of $30.68.
There are currently 57.98M OCS shares outstanding. The market value of OCS is $1.45B. In the past 24 hours, 113,000 OCS shares were traded.
How to Buy Oculis Holding Ag Stock
Wondering how to invest in Oculis Holding Ag stock? Here's how.
- Decide where to buy Oculis Holding Ag stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Oculis Holding Ag stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your investment account: Choose your method of payment and add your details.
- Evaluate Oculis Holding Ag stock: The Oculis Holding Ag ticker symbol is OCS. Is Oculis Holding Ag stock a good investment? Should you buy shares of OCS? How do OCS's underlying business fundamentals look? Do top analysts think Oculis Holding Ag is a good buy? Why has OCS's stock price moved recently? (Hint: Our stock research tools can help you figure out if OCS is a good stock to buy).
- Execute your OCS buy order: Decide if you will purchase OCS shares at the current market price or use a limit order to buy OCS stock at a specific price.
- Get key alerts regarding your OCS investment: Create a watchlist to important updates regarding your position in Oculis Holding Ag shares.
Step 1: Decide where to buy Oculis Holding Ag stock
You need a brokerage account to access the NASDAQ market and buy OCS shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal information so you can buy OCS today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new brokerage account.
- Send your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you have opened your account on the best stock trading app, your next step is to transfer the money for your investment:
Check out the video below for more details depositing money into your new brokerage account.
Step 4: Evaluate Oculis Holding Ag stock
After you have selected the best place to buy Oculis Holding Ag stock, it's very important to analyze their stock prior to investing, so you can understand the risk as well as the upside.
Oculis Holding Ag stock quick numbers
Oculis Holding Ag Fundamentals
WallStreetZen was built to help average investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on OCS's stock page.
How is OCS stock valued?
Analysts use many financial metrics, analyses, models, and charts to gauge OCS's fair value.
Using relative valuations methods:
- OCS could be overvalued based on its P/B ratio of 5.76x, relative to Biotechnology industry P/B ratio of 4.64x
You can access additional valuation analysis on OCS's stock here.
How do OCS Financials look?
Positive Financial Indicators:
- There are more short-term assets than short-term liabilities on the OCS balance sheet.
- There are more short-term assets than long-term liabilities on the OCS balance sheet.
- OCS has $273.09M in cash and short term investments. This is sufficient to cover its annual cash burn of $85.39M.
- OCS has cash burn of 85391025. It has sufficient cash and short-term investments to cover this for at least one year.
- OCS has a low debt to equity ratio of 0.2.
- Total OCS debt is lower than 5 years ago, relative to shareholder equity.
Negative Financial Indicators:
- OCS profit margin has gone up by 42.51 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy Oculis Holding Ag stock, according to Wall Street analysts?
Out of 6 sell side analysts who monitor OCS, the consensus analyst rating on Oculis Holding Ag is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Latest OCS Analyst Recommendations
Jason Gerberry, a top 15% analyst from Bank of America maintains OCS with a strong buy rating and lowers their OCS price target from $30.00 to $29.00, on Nov 13, 2025.
Daniil Gataulin, a top 3% analyst from Chardan Capital maintains OCS with a strong buy rating and maintains their OCS price target from $51.00 to $51.00, on Nov 11, 2025.
You can dig deeper into what analysts are saying on the Oculis Holding Ag stock forecast page.
OCS Trading Indicators
OCS Earnings
Last year, OCS revenue was $1.54M. Over the last five year, OCS's revenue has increased by 6.11% per year. This was slower than the Biotechnology industry average of 29.11%.
Learn more about OCS's earnings and revenue performance here.
What are OCS insiders up to?
Over the past 12 months, insiders at OCS have not bought or sold any shares.
Get more info about who owns OCS shares here.
Does OCS stock generate passive income?
No, Oculis Holding Ag doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Execute your OCS buy order
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally fine. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at an exact price, place a limit order.
Hit the Open button and eToro will place the order.
If you need additional assistance buying stocks on eToro, click the helpful video below:
Step 6: Get key alerts regarding your OCS investment
Now that you own some shares in OCS, you'll want to stay up-to-date on your stock purchase.
Start a watchlist to track the most important metrics related to your OCS stock.
OCS Feed
How to Buy Stock in Oculis Holding Ag
To reiterate, here are the 6 steps to buy Oculis Holding Ag stock:
- Decide where to buy Oculis Holding Ag stock
- Create your brokerage account
- Deposit money your investment account
- Evaluate Oculis Holding Ag stock
- Execute your OCS buy order
- Get key alerts regarding your OCS investment
If you need a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Oculis Holding Ag, get started below.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.